Verisante provides update on MSI system for skin cancer detection
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has provided an update on its website regarding the development of its rapid multispectral imaging (MSI) system for skin cancer detection. The MSI device...
View ArticleIn conversation with James Howard-Tripp
James Howard-Tripp As executive chairman of GeneNews (TSX:GEN; OTC:GNWSF), James Howard-Tripp is a veteran of pharma and biotech management and company creation, which included a long stint as CEO of...
View ArticleVerisante expands its sales and marketing team
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has hired Jason Mangler as director of sales to guide the company’s worldwide sales and marketing strategy and also hired Kim Ellis as its sales...
View ArticleVerisante receives Chinese patent for endoscopy imaging
The Chinese Patent Office has granted Verisante Technology’s (OTCQX:VRSEF; TSX-V:VRS) patent application entitled, “Methods and Apparatus for Measuring Cancerous Changes from Reflectance Spectral...
View ArticleVerisante completes Core prototype
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has completed the development of the Core series commercial prototype to aid in the detection of lung cancer. The Core system, which is based on the same...
View ArticleVerisante receives F&S technology innovation award
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has received the Frost & Sullivan 2014 North American Technology Innovation Leadership of the Year Award for In Vivo Cancer Detection for its skin...
View ArticleVerisante in preliminary license agreement for upper GI cancer detection...
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has signed a letter of intent with Astoria Capital SA, to sublicense and, in turn, finance the development and commercialization of Verisante’s cancer...
View ArticleVerisante displays Aura at BC Cancer Foundation
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is partnering with the BC Cancer Foundation to showcase Verisante Aura, a device for the rapid detection of skin cancer. Aura “We are very appreciative of...
View ArticleVerisante in sales pact for Core device in China
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has closed a $300,000 private placement in conjunction with signing a letter of intent with a strategic partner for the exclusive marketing and sales...
View ArticleVerisante begins FDA approval process for Aura
Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has initiated communications with the FDA for the approval of Aura, a device for the detection of skin cancer. “Verisante has now submitted documents to...
View Article
More Pages to Explore .....